← All trials
NCT04400695
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2020
- Primary completion
- Oct 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- May 25, 2020
- Last posted
- May 25, 2020
- Enrollment
- 366
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- RemeGenLead sponsor
- Peking UniversityOverall official - principal investigator
- Xiamen UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Anhui Medical UniversityOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Shandong UniversityOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Jinan UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- Jilin Provincial Tumor HospitalOverall official - principal investigator
- Dalian Medical UniversityOverall official - principal investigator
- Guizhou Medical UniversityOverall official - principal investigator
- Wuhan UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Shantou UniversityOverall official - principal investigator
- Xuzhou Medical UniversityOverall official - principal investigator
- Weifang People's HospitalOverall official - principal investigator
- Jiangsu Cancer Institute & HospitalOverall official - principal investigator
- Shanghai Xuhui District Central HospitalOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- Chengde Medical UniversityOverall official - principal investigator
- Qingdao UniversityOverall official - principal investigator
- Bethune International Peace HospitalOverall official - principal investigator
- Guangxi Medical UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Linyi Tumour HospitalOverall official - principal investigator
- Neijiang Second People's HospitalOverall official - principal investigator
- Xinxiang Medical UniversityOverall official - principal investigator
- Weihai Municipal HospitalOverall official - principal investigator
- Central Hospital, ZiboOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.